XML 33 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2012
Sep. 30, 2016
USD ($)
shares
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
Segment
shares
Sep. 30, 2015
USD ($)
shares
Dec. 31, 2015
USD ($)
shares
Nov. 30, 2015
USD ($)
Jun. 30, 2015
Tranche
Mar. 05, 2015
USD ($)
Dec. 31, 2014
shares
May 31, 2014
USD ($)
Dec. 31, 2012
USD ($)
Dec. 06, 2012
USD ($)
Significant Accounting Policies [Line Items]                          
Sales discount percentage   2.00%   2.00%                  
Sales discount term       30 days                  
Trade receivables, credit period       30 days                  
Number of tranches for private placement transaction | Tranche               2          
Accounts receivable written off   $ 0   $ 0                  
Other long-term assets   $ 682,000   $ 682,000   $ 174,000              
Warrants outstanding | shares   0   0                  
Gain (loss) on change in fair value of derivative liabilities   $ 3,610,000 $ (230,000) $ 8,170,000 $ (366,000)                
Number of operating segments | Segment       1                  
BioPharma Debt                          
Significant Accounting Policies [Line Items]                          
Maximum repayment of future revenue and receivables   128,800,000   $ 128,800,000                 $ 150,000,000
Fair value of embedded derivative liability                         $ 14,600,000
Gain (loss) on change in fair value of derivative liabilities       5,500,000 (300,000)                
Preferred Stock Purchase Option                          
Significant Accounting Policies [Line Items]                          
Gain (loss) on change in fair value of derivative liabilities         (946,000)                
Derivative liability at fair value                 $ 900,000        
Embedded Derivative Financial Instruments                          
Significant Accounting Policies [Line Items]                          
Gain (loss) on change in fair value of derivative liabilities       8,170,000 $ 470,000                
Embedded Derivative Financial Instruments | BioPharma Debt                          
Significant Accounting Policies [Line Items]                          
Maximum repayment of future revenue and receivables                       $ 150,000,000  
Fair value of embedded derivative liability   0   0   5,500,000              
Gain (loss) on change in fair value of derivative liabilities       $ 5,500,000                  
Top Three Customers | Gross Product Sales | Customer Concentration Risk                          
Significant Accounting Policies [Line Items]                          
Concentration risk percentage       95.00% 95.00%                
Top Three Customers | Accounts Receivable | Customer Concentration Risk                          
Significant Accounting Policies [Line Items]                          
Concentration risk percentage       95.00% 95.00%                
Convertible Debt | 2014 Notes                          
Significant Accounting Policies [Line Items]                          
Convertible senior notes, discount                     $ 27,900,000    
Fair value of embedded derivative liability           2,100,000              
Gain (loss) on change in fair value of derivative liabilities       $ 2,100,000 $ 800,000                
Derivative liability at fair value                     $ 3,500,000    
Convertible Debt | 2015 Notes                          
Significant Accounting Policies [Line Items]                          
Convertible senior notes, discount             $ 3,800,000            
Fair value of embedded derivative liability           $ 600,000              
Gain (loss) on change in fair value of derivative liabilities       600,000                  
Derivative liability at fair value             $ 500,000            
Convertible Debt | 2014 Notes and 2015 Notes                          
Significant Accounting Policies [Line Items]                          
Derivative liability fair value assumptions, dividend yield           25.60%              
Derivative liability fair value assumptions, risk-free rate           2.90%              
Derivative liability fair value assumptions, volatility rate           89.00%              
Convertible Debt | 2012 Notes                          
Significant Accounting Policies [Line Items]                          
Convertible senior notes, discount   $ 0   $ 0   $ 0              
Note, expected term 24 months                        
Non Cash | Convertible Debt | 2014 Notes                          
Significant Accounting Policies [Line Items]                          
Convertible senior notes, discount           24,100,000              
Non Cash | Convertible Debt | 2015 Notes                          
Significant Accounting Policies [Line Items]                          
Convertible senior notes, discount           $ 4,200,000              
Warrants Issued October 2009                          
Significant Accounting Policies [Line Items]                          
Warrants outstanding | shares   0   0   0       8,087,388      
Warrants exercised | shares         1,844,585                
Warrants expired | shares         6,242,803                
Accounting Standards Update 2015-03 | Convertible Debt | 2014 Notes                          
Significant Accounting Policies [Line Items]                          
Other long-term assets           $ (1,800,000)              
Accounting Standards Update 2015-03 | Convertible Debt | 2015 Notes                          
Significant Accounting Policies [Line Items]                          
Other long-term assets           (100,000)              
Accounting Standards Update 2015-03 | Scenario, Adjustment                          
Significant Accounting Policies [Line Items]                          
Other long-term assets           (1,900,000)              
Unamortized debt issuance cost           $ 1,900,000              
ASU No. 2016-09                          
Significant Accounting Policies [Line Items]                          
Excess tax provision on stock-based awards   $ 300,000   $ 400,000                  
Deferred tax assets   $ 1,600,000   $ 1,600,000                  
ASU No. 2016-09 | Scenario, Previously Reported                          
Significant Accounting Policies [Line Items]                          
Excess tax provision on stock-based awards         $ (700,000)                
ASU No. 2016-09 | Restatement Adjustment                          
Significant Accounting Policies [Line Items]                          
Excess tax provision on stock-based awards         $ 700,000                
Minimum | Embedded Derivative Financial Instruments | BioPharma Debt                          
Significant Accounting Policies [Line Items]                          
Derivative liability fair value assumptions, term       1 year 3 months 18 days   2 years              
Derivative liability fair value assumption, coupon rate       6.60%   6.60%              
Derivative liability fair value assumptions, market yields       9.30%   13.00%              
Maximum | Embedded Derivative Financial Instruments | BioPharma Debt                          
Significant Accounting Policies [Line Items]                          
Derivative liability fair value assumptions, term       5 years 7 months 6 days   7 years 3 months 18 days              
Derivative liability fair value assumption, coupon rate       12.50%   12.50%              
Derivative liability fair value assumptions, market yields       30.70%   30.70%